Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Temporary Pure Red-Cell Aplasia During Valproate Monotherapy: Clinical Observations and Spectral Electroencephalographic Aspects

View through CrossRef
We report the case of a 4-year-old boy with pure red-cell aplasia associated with sodium valproate monotherapy. Treatment with valproate was initiated because of idiopathic tonic-clonic seizures; he became free of seizures. During the introduction of and ongoing antiepileptic drug treatment, clinical and laboratory controls using electroencephalographic (EEG) spectral analysis were performed at regular intervals and disclosed normal values. Ten months after the introduction of valproate, clinical examination was normal except for marked pallor. Peripheral blood showed macrocytic anemia and the bone marrow finding was isolated absolute erythroblastopenia. At the same time, significant changes in EEG background activity were present as well-defined slowing. There was an increase in the relative power of theta activity and a decrease in alpha 2 activity in the occipital regions. Valproate was discontinued and phenobarbital therapy introduced. A complete resolution of the hematologic damage was observed after valproate withdrawal. Recovery of the hematologic parameters started 14 days after discontinuation of valproate therapy, while normalization of EEG background activity was observed earlier. The patient maintained stable hematologic values and seizure control without disturbances of the spectral EEG. After 6 months of phenobarbital therapy, re-administration of sodium valproate was not followed by recurrence of any clinical or electrophysiologic symptoms or abnormalities. (J Child Neurol 2000;15:485-487).
Title: Temporary Pure Red-Cell Aplasia During Valproate Monotherapy: Clinical Observations and Spectral Electroencephalographic Aspects
Description:
We report the case of a 4-year-old boy with pure red-cell aplasia associated with sodium valproate monotherapy.
Treatment with valproate was initiated because of idiopathic tonic-clonic seizures; he became free of seizures.
During the introduction of and ongoing antiepileptic drug treatment, clinical and laboratory controls using electroencephalographic (EEG) spectral analysis were performed at regular intervals and disclosed normal values.
Ten months after the introduction of valproate, clinical examination was normal except for marked pallor.
Peripheral blood showed macrocytic anemia and the bone marrow finding was isolated absolute erythroblastopenia.
At the same time, significant changes in EEG background activity were present as well-defined slowing.
There was an increase in the relative power of theta activity and a decrease in alpha 2 activity in the occipital regions.
Valproate was discontinued and phenobarbital therapy introduced.
A complete resolution of the hematologic damage was observed after valproate withdrawal.
Recovery of the hematologic parameters started 14 days after discontinuation of valproate therapy, while normalization of EEG background activity was observed earlier.
The patient maintained stable hematologic values and seizure control without disturbances of the spectral EEG.
After 6 months of phenobarbital therapy, re-administration of sodium valproate was not followed by recurrence of any clinical or electrophysiologic symptoms or abnormalities.
(J Child Neurol 2000;15:485-487).

Related Results

Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
Valproate Annual Risk Acknowledgement Form: Evaluating Compliance and Creating Digital Solutions
Valproate Annual Risk Acknowledgement Form: Evaluating Compliance and Creating Digital Solutions
Aims: Valproate is a commonly prescribed drug in neurology and psychiatry, licensed for epilepsy as an anticonvulsant and in bipolar disorder as a mood stabilis...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
2254 A Rare Case of Valproate-Induced Encephalopathy Requiring Hemofiltration
2254 A Rare Case of Valproate-Induced Encephalopathy Requiring Hemofiltration
INTRODUCTION: We present a rare case of acute encephalopathy due to Valproate induced hyperammonemia required Hemofiltration (HF). CAS...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
The Impact of Sodium Valproate on Male Reproductive Health: A Comprehensive Review
The Impact of Sodium Valproate on Male Reproductive Health: A Comprehensive Review
Sodium Valproate is one of the most prescribed antiepileptic drugs and it leads to severe reproductive problems among men. The objective of this review is to provide an overview ab...
Fetal Valproate Syndrome – Still a Problem Today!
Fetal Valproate Syndrome – Still a Problem Today!
Abstract Introduction Fetal exposition to valproate can lead to a cluster of facial dysmorphism, congenital anomalies and neurodevelopmental retardation. Case Report In this report...

Back to Top